Crossref
Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy
Breast Cancer Management · 2016
DOI: 10.2217/bmt-2017-0006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Management, 2016. Verfasst von David Montgomery. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Montgomery, D. (2016). Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy. Breast Cancer Management. https://doi.org/10.2217/bmt-2017-0006
Vancouver
Montgomery D. Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy. Breast Cancer Management. 2016. doi:10.2217/bmt-2017-0006
BibTeX
@article{Montgomery2016,
author = {Montgomery, David},
title = {Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy},
journal = {Breast Cancer Management},
year = {2016},
doi = {10.2217/bmt-2017-0006}
}
EUVIMED